Abstract Number: 2113 • ACR Convergence 2025
Mortality rate in patients with hip fracture: is it recommendable to establish fracture units?
Background/Purpose: Hip fracture is the second most common osteoporotic fracture and the one with the highest socio-economic cost. It is associated with high morbidity and…Abstract Number: 2112 • ACR Convergence 2025
Which drugs are associated with the development of osteonecrosis of the jaw? clinical and epidemiological analysis of a cohort of patients diagnosed with osteonecrosis of the jaw.
Background/Purpose: Osteonecrosis of the jaw (ONJ) is defined as avascular necrosis of bone located in the maxillofacial region with the presence of exposed bone or…Abstract Number: 2107 • ACR Convergence 2025
Experience of a Fragility Fracture Coordination Unit Integrated Across Two Hospitals: An Innovative Multidisciplinary Model for Optimizing the Management of Geriatric and Non-Geriatric Patients Beyond Surgery After an Osteoporotic Bone Fragility Fracture
Background/Purpose: Fracture Coordination Units typically function within a single hospital using a multidisciplinary approach. Our unit, established in February 2024, pioneers a model coordinating care…Abstract Number: 0351 • ACR Convergence 2025
Experience with romosozumab in women with osteoporosis at high risk of fracture in real-world clinical practice
Background/Purpose: Romosozumab (RMZ) is a recently approved dual-acting drug which has been shown to reduce fracture risk in patients with osteoporosis (OP) in clinical trials.…Abstract Number: 0350 • ACR Convergence 2025
Perioperative Evaluation of Blood Tests Including Bone Turnover Markers in Patients Undergoing Surgery for Proximal Femur Fractures
Background/Purpose: Osteoporosis treatment is essential to prevent fractures. However, few patients with proximal femur fractures receive osteoporosis treatment before injury. Initiating treatment postoperatively is critical…Abstract Number: 2563 • ACR Convergence 2024
Efficacy and Safety Results of CT-P41 (Proposed Denosumab Biosimilar) Compared to Reference Denosumab in Postmenopausal Women with Osteoporosis: 78-Week Results from Phase 3 Randomized Controlled Trial
Background/Purpose: CT-P41 is a proposed biosimilar of the reference denosumab (DEN), a fully human monoclonal antibody that binds the cytokine receptor activator of NF-κb ligand…Abstract Number: 2112 • ACR Convergence 2024
Discontinuation and Non-Publication of Osteoporosis Studies: An Observational Analysis of 7,670,624 Patients
Background/Purpose: Osteoporosis (OP) is one of the most common diseases, especially in old age, and as the population ages, the burden of osteoporosis is expected…Abstract Number: 2113 • ACR Convergence 2024
Discontinuation and Non-publication of Postmenopausal Osteoporosis Clinical Studies: A Cross-sectional Analysis of 345,435 Patients
Background/Purpose: Postmenopausal osteoporosis (PMOP) significantly contributes to global fracture rates annually, with its silent progression complicating early detection and intervention. Effective management strategies are crucial,…Abstract Number: 2116 • ACR Convergence 2024
Artificial Intelligence Classifier for Osteoporosis Detection from Chest Radiographs: Performance Evaluation and Literature Comparison with Quantitative Ultrasound
Background/Purpose: Osteoporosis is a common condition that often goes unnoticed until it results in fractures, significantly increasing morbidity and mortality rates. Recent advancements in deep…Abstract Number: 2130 • ACR Convergence 2024
Post-fracture Survival for Rheumatoid Arthritis Patients Is Not Improving
Background/Purpose: Improved disease control for articular manifestations of Rheumatoid arthritis (RA), has resulted in more attention being directed to extra-articular (ExRA) manifestations (cardiovascular events, osteoporosis,…Abstract Number: 2144 • ACR Convergence 2024
Impact of Immunogenicity on Clinical Outcomes in Postmenopausal Women with Osteoporosis: Results from a Randomized Controlled Phase 3 Study to Compare CT-P41 (Proposed Denosumab Biosimilar) and Reference Denosumab
Background/Purpose: CT-P41 has been developed as a proposed biosimilar of the reference denosumab (DEN), a fully human monoclonal antibody that binds the cytokine receptor activator…Abstract Number: 0998 • ACR Convergence 2023
Barriers and Facilitators for Osteoporosis and Sarcopenia Care for Persons Living with HIV in Peru: HIV Physician and Coordinator Perspectives
Background/Purpose: Persons living with HIV (PLWH) have a higher risk of developing age-related non-communicable diseases (NCDs), such as osteoporosis and sarcopenia. In Peru, HIV providers…Abstract Number: 1997 • ACR Convergence 2023
A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis
Background/Purpose: SB16 is a human monoclonal antibody to the receptor activator of nuclear factor κΒ ligand that has been developed as a proposed biosimilar to…Abstract Number: 2123 • ACR Convergence 2023
Dose Trabecular Bone Score (TBS) Add Predictive Value to Fracture Risk Assessment (FRAX) in Rheumatoid Arthritis?
Background/Purpose: Trabecular bone score (TBS) of lumbar spine is a dual X-ray densitometry (DXA)-based tool to evaluate bone microarchitecture, providing information on bone quality in…Abstract Number: 0070 • ACR Convergence 2022
Post-operative Delirium and Cognitive Impairment: An Analysis of Predictors and 120-day Outcomes in England Using the National Hip Fracture Database (NHFD)
Background/Purpose: Post-operative delirium and cognitive impairment are common after hip fracture. We set out to identify risk factors and examine the association with returning home…
ACR Meeting Abstracts